Evidence for a graft-versus-lymphoma effect
| Lymphoma . | No. of patientsin CCR . | Effect . | Reference (year) . |
|---|---|---|---|
| Follicular | 8/13 | DLI | Marks et al19 (2002) |
| Mantle cell | 15/18 | DLI | Khouri et al167 (2003) |
| High grade | 8/9 vs 0/9 | T-cell depletion | Glass et al168 (2004) |
| Hodgkin | 5/7 | DLI | Peggs et al169 (2007) |
| T-NHL | 12/17 | RIC + DLI | Corradini et al99 (2004) |
| CLL | 8/9 | MRD | Ritgen et al103 (2004) |
| Lymphoma . | No. of patientsin CCR . | Effect . | Reference (year) . |
|---|---|---|---|
| Follicular | 8/13 | DLI | Marks et al19 (2002) |
| Mantle cell | 15/18 | DLI | Khouri et al167 (2003) |
| High grade | 8/9 vs 0/9 | T-cell depletion | Glass et al168 (2004) |
| Hodgkin | 5/7 | DLI | Peggs et al169 (2007) |
| T-NHL | 12/17 | RIC + DLI | Corradini et al99 (2004) |
| CLL | 8/9 | MRD | Ritgen et al103 (2004) |
DLI indicates donor lymphocyte transfusion; RIC, reduced intensity conditioning; MRD, minimal residual disease; T-NHL, T-cell non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; and CCR, continuous complete remission.